Vol. 99, No. 3,198l April
BIOCHEMICAL
AND
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
15, 1981
Pages 820-829
ONLY ONE TYPE OF BENZO(A)PYRENE-DNA ADDUCT IS DETECTED IN TRANSFORMABLE MOUSE CELLS Ko-yu Cell
Received
Lo and Takeo
Kakunaga
Genetics Section, Laboratory of Molecular National Cancer Institute, National Institute Bethesda, Maryland 20205
February
Carcinogenesis of Health
24,1981
Summary When highly transformable BALB/3T3-A31 clone 1-13 cells are exposed to benzo(a)pyrene for various lengths of time, only one type of carcinogen-DNA adduct is detected. No minor adducts were found as reported in other cell systems. High pressure liquid chromatography identified this persistent adduct as lo-trans-7R-benzo(a)pyrene diolepoxide Ideoxyguanosine. Formation of benzo(a)pyrene-deoxyguanosine adduct, therefore, appears sufficient to initiate the transformation process induced by benzo(a)pyrene in 1-13 cells. Introduction The prevailing that
covalent
initiation only
adducts
covalent
could
of 06-alkyl
formed to
be the
both
arylamidated
in
liver
DNA;
persistent
deoxyguanosine
susceptibility
of these
in
lesion certain
tissues
bound
process.
amide, rat
a crucial
of reports
remain
such
carcinogenesis
DNA is
number
which for
chemical to
A growing
be essential
were
in
carcinogens
adducts
aromatic
been found
theory
of
of neoplasia.
carcinogen,
the
binding
those
periods
genetic
tissues
DNA for
N2-and only
vivo
to carcinogenesis
the that
extended with
liver
C8-deoxyguanosine the
N2-adduct
(l-4). has
in
indicated
For examples,
however, in
step
have to
argues
has
The persistence
been
correlated
with
(5-8).
Abbreviations used: BP, benzo(a)pyrcne; BPCE 1,(&l-78, 8a-dihydroxy%,lOa-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, diol epoxide I, r-7,t-8dihydroxy-t-9,10-oxy-7,8,9,lO-tctrahydrobenzo(a)pyrene; BPDE II, (t)-7B,8adihydroxy-98,106-epoxy-7,8,9,lO-tetrahydrobenzo(a)pyrene, diol epoxide II, r-7,t-8-dihydroxy-c-?,lO-oxy-7,8,9,lO-tetrahydroxybenzo(a)pyrene, IO-trans7R-BPDE I-d&a, N2-(10S-[7R,8S,9R-trihydroxy-7,8,9,lO-tetrahydrobenzo(a)pyrene]yl-deoxyguanosine; dGua, deoxyguanosine; HPLC, high-pressure liquid chromatography; PBS, phosphate buffered saline; HEC, hamster embryo cells; MEF, secondary mouse embryo, cell; BHK, baby hamster kidney cells. 0006-291X/81/070820-10$01.00/0 Copyright 0 1981 by Academic Press, Inc. All rights of reproduction in any form reserved.
820
BIOCHEMICAL
Vol.59,No.3,1981
Benzo(a)pyrene strong
(BP)
carcinogen. in mammalian
Although
BP-deoxyguanosine
examined
to the
human
than
deoxyguanosine
it
not
known
strongly We chose
BALB/3T3-A31 gives
high
susceptible provides
in the
investigate
clone
1-13
for
transformation system
produced
here
(i.e.
BPDE I-dGua)
line,
suggesting
that is
that
adducts
(13,18).
been
animals
(19).
formed
in all
rodent in
cells
nucleosites
At the
DNA modifications
BP-DNA
following (2)
present
are
induced
this
(1)
time
correlated
cell
by carcinogens
which
may play
produced This
the carcinogen-DNA
amount,
of cell
adducts
reasons:
Since
to detect
cell
line
is
(20),
it
adducts,
in line
highly
especially
an important
role
transformation.
only formed
BP
covalent
in minute
process
products
has
a
process.
the
to the
intact
transformable
minor
these
the
efficiency;
We report
Materials
of
the
produced
carcinogenic
to
initiation
transformation
types
plating
adducts
some
major
and
adducts
and in
the
from
were also
the
a sensitive
those
ranged
cells,
which
with
were
COMMUNICATIONS
contaminant
nucleoside
(9-18)
adducts
RESEARCH
environmental
BP-DNA
cultures
which
other
most
common of
tissue
systems,
resistant
is
a
Formation
detected
the
is
AND BIOPHYSICAL
one in
BPDE I-dGua
type
this itself
of highly is
persistent
BP-DNA
transformable sufficient
mouse to
initiate
adduct cell the
process.
and Methods.
Cell Cultures: Clone 1-13 isolated from mass culture of BALB/3T3-A31 was used (20). Cells were plated at 1~10~ cells per lo-cm tissue culture dish and were grown in Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum. Binding of [6-3H]BP to DNA: [6-3~1 BP (Amersham-Searle) was diluted with cold BP (Chemical Repository, NCI) to specific activity at 6-20 ci/mmoleie;;; iyrified by a gravity flow silica gel column (21) before use. 70% confluency were treated with [6-3~1 BP for the lengths of time specified. At the end of incubation, cells were washed once with ice-cold phosphate buffered saline (PBS) and collected by scraping. After harvesting, cells were again washed with PBS, suspended in 1OmM Tris-HCl (pH7.5), 1OmM EDTA, 1OmM NaCl, lysed by 0.5% sodium dodecyl sulfate (SDS) and treated with proteinase K at
821
BIOCHEMICAL
Vol. 99, No. 3,198l
AND
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
50ug/ml overnight. DNA was extracted twice with buffered saturated phenol containing 0.1% 8-hydroxyquinoline, and was then precipitated with two volumes of cold 95% ethanol. The precipitated DNA was further purified by digestion with RNase, phenol extraction and ethanol precipitation. DNA solutions were then heated to 100°C for 15 min to remove the possible intercalated hydrocarbon, passed through a short Sephadex LH20 (pharmacia) column (lxl5cm) and lyophilyzed to dryness. The amount of BP bound to DNA was determined by counting of samples of treated DNA in a Beckman LS8100 scintillation counter. Concentration of samples was determined by Burton reaction (22). Intracellular BP Pools: BP treated cells from two lo-cm culture dishes were rinsed twice with MEM, harvested with trypsin and resuspended in PBS at 2x106 cells/ml. 2 ml of cell suspension were lysed with 2ml of acetone and then extracted with 4 ml of ethyl acetate. Following removal of the organic phase, the aqueous phase was extracted with equal volume of acetone/ethyl acetate (1:2 v/v). The organic phases were combined, dehydrated, dried, and finally dissolved in 0.5 ml of benzene. BP was separated from its metabolites on a silica gel column as described by Okano et al (23). Analysis of [6-3H]BP-DNA Adducts: BP modified DNA samples were enzymatlcally hydrolyzed and the nucleoside mixture was chromatographed on Sephadex LH20 (24). The isolated nucleoside adducts were analyzed by high pressure liquid chromatography (HPLC, Waters Associated) fitted with a Zorbax ODS column (6.2 x 250mm, DuPont). Samples were eluted with a linear gradient from 40-88% Methanol-water over a 50-min period. Preparation-of BP-7,8-dihydrodiol 9,10-oxide (BPDE)-polynucleotide products: [JH]BPDE I (Chemical Repository, NCI) was reacted with poly d(G) and poly d(A) (P-L Biochemicals) for 18 hrs at 37°C in a tetrahydrofuranwater mixture (1:5, v/v, PH 7.0). After extraction with ethyl acetate, the polynucleotides were precipitated twice with ethanol. The BPDE Ipolynucleotide products were enzymatically hydrolyzed, separated on Sephadex LH20 column, and analyzed by HPLC as authentic markers.
Results
and Discussion
Previously,
we reported
BP produced
25 transformed
examined,
at
to DNA and of BP to
this
1-13
This for level
could
foci
of
cellular
DNA is
(or
even
suggest
DNA binding
that at
of DNA binding
104
of
carcinogen,
formed. shown
(0.5uM),
before)
in the
18 hr
of
no remaining
later seen
time in
l-13
surviving
The Fig.1. amount
cells
with
cells the
amount
time
course
with
Alternatively,
could
822
be due to equal
BP bound
of
binding
were
of BP bound
of
We then
of
When cells
incubation
0.5uM
(25).
exposed
to DNA reached the
BP or BP metabolites
points. Fig.1
of
per
BP adducts
of carcinogen at
treatment
concentration
types
to low level a plateau
that
carcinogen.
were the
available
steady
rates
state
of forma-
BIOCHEMICAL
Vol.99,No.3,1981
0
AND BIOPHYSICAL
10
20
30
RESEARCH
40
TIME AFTER ADDITION
50
COMMUNICATIONS
60
70
OF [sH]BPlhrsl
Time course of binding of [6-3H]BP to DNA in BALB/3T3-A31 Figure 1. cells were exposed to 0.5uM of [6-3H]BP. clone 1-13 cultures. -o-e-, After 18 hr incubation with the carcinogen, hydroxyurea was added to medium (final concentration, ImM) to inhibit semiconservative DNA -o-o-, "posttreatment incubation". Cells were exposed to synthesis. 0.5uM of [6-3~16~ for 18 hr. after which cells were rinsed with warm medium and then incubated in fresh BP free medium containing 1mM of -&-A, cells were exposed to Z.OuM of [6-3H]BP. DNA was hydroxyurea. isolated and the amount of BP bound to DNA was determined as described in Materials and Methods.
tion
and removal
of
been
reported
many mammalian
in
between
these
and in
intracellular
treatment in Table only the
BP-DNA adducts
possibilities,
1,
1% of
sequestering
1-13
cells
free
medium
were for
we studied
of
after BP
systems
BP pools.
incubation
of first various
the
incubation
in the
in
the
medium.
exposed lengths
to
fate
833
of
cells
18hr it
BP both
in
DNA repair carcinogen. 0.5uM
studies
of also
Furthermore,
and then
incubated the
medium
by postAs shown
cells.
followed
DNA has
To distinguish
with
pool
inside
of times,
BP damaged
of
monitored
BP
BP for
of
(11,13,18,26).
absence of
carcinogen
excision
the
We also
cells
18 hrs
remained
since
[6-3H]BP, suggested when with
same binding
BP
BIOCHEMICAL
Vol. 99, No. 3,198l
Table
I
Duration treatment (hr)
of
Intracellular
AND
Intracellular pools b plel 10 cell)
2/4
0.5 /Al
2 /AM
100.0 37.0 24.4 13.4
96.5 ND ND 1.0
;D” ND
::; 0.3
12 :: 40 65
lY7
a values obtained from two determinations b mean of 5 independent experiments c values in parentheses represent BP bound with BP free medium
as that
findings
support
of BP or its decrease
in
specific
activity
excised
cell
whether
the
susceptibility
when cells
were
of BP to
cellular
that
repair
in
medium
capacity
to
DNA increased or
order
in
to
the obtain
cells
interactions
by this
it
carcinogen,
gen in both
types
has to
used
be
is
better
of experiments. to
detect
with
the
and that
cells
of
1,
correlation and
the
cells
to
These
between
transformation
a higher
biochemical
824
in its
other
hand,
products,
the
binding available
data the
suggest study
process
concentration
and
role
as BP was
1).
two
determine
(2.OuM),
to use the same concentration If
over
On the
carcinogen
Table
indicated
a crucial
as long
is
low efficiency.
required
play
lack
small
incubation
extremely in the
These
the
Our results
are
time
(Fig.
relevant
chemical-biological
with
1).
is due to the
posttreatment
intact
level
(Fig.
reactions,
transformation.
high
of culture
of DNA binding
from DNA.
of 1-13
t.! 2.9 (3.1 F 3.0 (2.8) 2.9 (2.6)
incubation
was used
studies
BP-induced
exposed
ND
posttreatment
adducts
Further
to
6.7 5.0 6.6b ND 14.1” ND
after
of BP adducts
Extent of bindir$ (A mole BP/mole of nucleotides)
ND ON:4 0:14 0.15 0.12
further
BALB/3T3-
0.5 AM
6.5 ND ND ND
plateau
remained
BP
to
2rM
of DNA during
lesions
BP binding
COMMUNICATIONS
0.5 FM
medium
for
generations. low
the
carcinogen
80% of the
a half
in the
that
metabolites
cells
More than
high
idea
to the removal
1-13
to DNA
BP containing
active
attributable that
when the
RESEARCH
BP pools and extent of A31 clone 1-13 DNA.
% of BP remained in medium
ii
kinetics
BIOPHYSICAL
of
induced
of carcinoof carcinogen importance
of
BIOCHEMICAL
Vol.99,No.3,1981
these
products
in
relation
AND
BIOPHYSICAL
the
transformation
to
RESEARCH
COMMUNICATIONS
process
should
be
established.
DNA isolated was subjected
from to
chromatographed by high
relativey
large
enzymatic
total
cell
cells
in total with
and of
authentic
revealed
only
with
second
one
first
peak
accord skin in the
found
l-3%
of
in
relative in
in
abundance
of
7s enantiomer.
In the
--in
types
adduct
formed
of
BP-DNA
7R-BPDE I-dGua explants
(14).
BPDE II-dGua
was the In
vivo
only
adduct
addition
to
was formed
in
the
removed
from
explants
825
1-13
samples coincided
corresponded
cells
(HEC,13).
to This
radioactivity
rewith
the
of BPDE I-dGua,l3). by
1-13 cells
not as
have
system
produced this
DNA digest
all
to
cells
is
(18),
Mouse
observed that
at a faster
which
of were
which
lOT1/2
isomers
systems vary
purine
total
by
fraction
position
We did
two
is
either
DNA digests
of
isomer
(27).
I-dGuo
1-13
enantiomer
embryo
these
prevent
was associated
BPDE I
mouse
microsomes
7R-BPDE
the
were
may be produced
elution
radioactivity
liver
which
of
(7s
to
[14C]
embryo
was
We have employed
which
adducts,
adducts
finding
adducts
digests
hamster
of
nucleoside
of
Its
97-99%
synthesis
and
HEC (13),
in
mixture
by a negligible
The
deoxyguanosine
remaining
the
(19),
2). peak.
of deoxyguanosine
with
peaks
BPOE I modified
contributed
The stereoselective
minor
[6-3H]BP
nucleoside
HPLC studies
HPLC profiles
(Fig.
and ~.OJJM of
(HPLC).
be produced
markers
of
isolated
for
the
of
I-dGua
The
samples
profiles
peak
the
chromatography
radioactive
isomer
covered.
of
to 0.5&M and
The
population.
the
lo-trans-7R-BPDE predominant
liquid
or might
cell
compared
LH20.
overestimating
population
exposed
hydrolysis
pressure amount
or
the
cells
on Sephadex
analyzed
overlooking
1-13
changes
reported rate
been
in human and bovine
major
adduct,
small
of
human colon
(15),
in
than
its
studied,
system.
in
the
lo-transbronchial amount lung
of (16),
Vol. 99, No. 3,198l
BIOCHEMICAL
AND
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
HPLC profiles of-DNA adducts formed in BALB/3T3-A31 clone l-13 %%%%incubated-with [6-JH]BP. (a) vitro marker from digest of --in BPDE I modifi ed ["C] purine DNA. (b) in vitro marker formed by reaction of C3H] BPDE I with polv d(G) and uolv7dx fispectively. (c)-(e) DNA adducts isolated from'l-i3 ckl'ls after i2 hr (c), 18 hr (d), and 40 hr (e) exposure to Z.OuM of [6-3H] BP. DNA isolated frown cells exposed to D.!%M of [6-3H]BP exhibits an identical elution pattern.
826
BIOCHEMICAL
Vol. 99, No. 3.1981
and in
secondary
mouse embryo
was also
detected
dGua at
comparative
(BHK,II)
and
of BPDE
I-dGua
both
in
and
are
readily
of these
cells
(18).
tumor
cells
transformed
baby
hamster
kidney
(17).
mouse
adducts,
small
are
also
carcinogen.
cells
skin
(19).
amounts
to
transforcells
(32)
It is not known which
types
most strongly
lOT1/2
of
Cells
found.
resistant and
BPDE II-
7s enantiomers
in
HEC (28-31)
are correlated
The
were
human cells,
by this
BP-DNA adducts
and
adducts
However,
BP.
adduct
BPDE I-
and BPDE II-dGua
like
COMMUNICATIONS
Both
produced
deoxycytidine
systems, by
in
were
RESEARCH
The deoxycytidine
found
II-dGua
BPDE Iand
induced
(MEF,ll).
were
BPDE
besides
of some of these
cells
human alveolar
deoxyadenosine
mation
lOT1/2 level
A549
In HEC (13),
AND BIOPHYSICAL
with
the carcinogenic
process.
Minor
adducts
have been systems
(11,13,17). the
Our assays
are
is
extented
provided step
in
l-13
that
periods. for
that
in chemical
the the
in all
they
probably
represent
minor
transformation
them to be the
of binding
is
than major
transformation
carcinogenesis.
827
carcinogen
in
some
not
the of
examined.
as little Should less
as minor
than
are
0.1%
a thousand
deoxyguanosine
cause of transformation.
persistent
formation
of
adducts
adducts
one type
at quantities
these
is
the DNA samples
cells
Unless
this only
produced.
Therefore,
covalent
since
adducts
BPDE I-dGua
induction
that
cells,
adducts
processes
total
formed.
for
of multiple
the
in inducing
show
indicate
1-13
minor
of excision
transformation
was observed
of
impossible
also
and clearly
detect
that
adducts
responsible
results
to
more efficient
Our data over
of
total
it
Our
rate
transformable
able
be formed
adduct,
mutagenic
(BPDE I-dGua)
one thousandth
fold
in
highly
BP-DNA adduct
adducts
and differential
implicated
case with
of the
(33)
of by
in
BP-treated
this
adduct
BP in
to DNA is
1-13
cells appears cells,
a necessary
Vol.99,No.3,1981
BIOCHEMICAL
AND
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
ACKNOWLEDGEMENTS The authors wish to thank Drs. M. Osborne and P. Brookes for providing [14C] purine DNA, and Dr. R.S. Day III for critically reviewing this manuscript.
References 1. ;: 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27.
Epstein, S.M., McNary, J., Bartus, B. and Farber, E. Science, 162, 907-908 (1968). 29 1799-1804 (1969). Irving, C;C., -and Veazey, R.A. Cancer Res., Kriek, E. Cancer Res.. 32 2042-2m 19f2): Kriek, E. and Hengev e1d.G.M. Chem-Bioi. Interact., 21, 179-201 (1978). Goth, R. and Rajewsky, M.F. oroc. Natl. Acad. Sci. Un, 71, 639-643 (1974). Biochem,J., 148, 521-525 (1974). Margison, G.P. and Kleihues, P. Cox, R. and Irving, C.C. Cancer Lett., 3, E5-m(1977). Cox, R. and Irving, C.C. Cancer Lett., 5, 273-278 (1979). Grover, P.L., Hewer, A., Pal, K. and Sims, P. Int. J. Cancer, 3, l-6 (1976). Jeffrey, A.M., Jennette, K.W., Blobstein, S.H., Weinstein, I.B., Beland, F.A., Harvey, R.G., Kasai, H., Miura, I. and Nakanishi, K. J. Am. Chem. Sot., 98, 5714-5715 (1976). Shinohara, K. and Terutti, P.A. Proc. Natl. Acad. Sci. USA, -74 979-983 (1977). Baird, W.M. and Diamond, L. Biochem. Biophys. Res. Commun., 11, 162-167 (1977). Ivanovic, V., Geacintov, N.E., Yamasaki, H. and Weinstein, I.B. &gq# '-'w;i+"t;;1,60: g978ynette K w Grzeskowiak, K., Nakani;hi, c', Harvey, R:G., Asrup, H. aid H&-;s, C.C. Nature, 269, 348-350 (1977). C.C., Trump, B.F. and Jeffrey, A.M. Cancer Res., Autrup, H., Harris, 38. 3689-3696 119781. Feldman, G., Remsen,J., Shinohara, K. and Cerutti, P.A. Nature,=, 796-798 (1978). Cerutti, P.A., Sessions, F., Hariharam, P.V. and Lusky, A. Cancer m., 38, 2118-2124 (1978). Brown, 7i;S., Jeffrey, A.M. and Weinstein I.B. Cancer Res., 2, 1673-1677 (1979). Koreeda, M.; Moore, P.D., Wislocki, P.G., Levin, W., Conney I, A.H., Yagi, H. and Jerina, D.M. Science, 199, 778-781 (1978). Kakunage, T. and Crow, J.D.,Sciencexx, 505-507 (1980). Selkirk, J.K., Plotkin,E.V. and Gelboin, H.V. Cancer Yang, S.K., (1975). &. , 35, 3642-3650 Burton, K. Biochem. J., 62, 315-323 (1956). Cancer Okano, P., Miller, H.N., Robinson, R.C. and Gelboin, H.V. &., 2, 3184-3193 (1979). Lo, K. and Kakunaga, T. in preparation. Kakunaga, T., Lo, K., Crow, -J.D., and Augl, C. proc. Am. Assoc. Cancer Res., 2J, 350 (1980). Mutation Res., 50, Day, R.S., Scudiero, D. and Dimattina, M., 384-394 (1978). P.P. and Gelboin, H.V. Proc. Yang, S.K., McCourt, D.W., Roller, Natl. Acad. Sci., USA, 3, 2594-2598 (1976).
828
Vol. 99, No. 3,1981
28. 29. 30. 31. 32. 33.
BIOCHEMICAL
AND
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
Berwald, Y. and Sachs, L. J. Natl. Cancer Inst.,%, 641-661 (1965). Dipaolo, J.A., Donovan, P. and NmR.1. Cancer Inst., 2, 867-874 (1969). Heidelberger, C. Chemical Carcinogenesis. Ann. Rev. Biochem., 44, 79-121 (1975). Mager, R., Huberman, E., Yang, S.K., Gelboin, H.V. and Sachs, L. Int. J. Cancer, 19, 814-817 (1977). Mondal, S., Bra&w, D.W. and Heidelberger, C. Cancer Res., 36, 2254-2260 (1976). Kakefuda, T. And Yamamoto, H. Proc. Natl. Acad. Sci. USA, 3, 415-419 (1978).
829